FDA Approves Teva’s SYNRIBO® (Omacetaxine Mepesuccinate) for Injection for Home Administration

[Business Wire] – Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has approved SYNRIBO® for injection, for subcutaneous use, to include home administration, and also approved a related Medication Guide and more

View todays social media effects on TEVA

View the latest stocks trending across Twitter. Click to view dashboard

See who Teva is hiring next, click here to view